24/7 Market News Snapshot 31 March, 2025 – CERo Therapeutics Holdings, Inc. Common Stock (NASDAQ:CERO)

March 31, 2025

DENVER, Colo., 31 March, 2025 (247marketnews.com) – (NASDAQ:CERO) are discussed in this article.
CERO Therapeutics Holdings, Inc. is currently facing a downward trend, with a pre-market stock price of $0.692, indicating a significant drop of approximately 7.86% from the previous closing price of $0.751. This decline is accompanied by a substantial pre-market trading volume of 4.86 million shares, suggesting increased market activity that may be influenced by recent news or broader market shifts. As the stock struggles to maintain upward momentum, traders should be vigilant for potential reversal signals or further declines, taking both technical indicators and overarching market trends into account.

Amid these market challenges, CERO has made significant strides in its immunotherapy development. The company recently announced that it received clearance from the U.S. Food and Drug Administration (FDA) for a second Investigational New Drug (IND) application for its lead compound, CER-1236. This approval will facilitate a Phase 1 clinical trial aimed at treating advanced solid tumors, specifically non-small cell lung cancer and ovarian cancer.

Dr. Robert Sikorski, Chief Medical Officer at CERO, voiced excitement over this milestone, stating, “Following the launch of our AML trial, we are now initiating a second clinical study of CER-1236 to explore its potential in solid tumors, offering new therapeutic options to patients battling ovarian and lung cancer.” He emphasized that CER-1236 is the first CAR-T cell therapy designed to target Tim-4L, integrating phagocytic activity directly into T cells. Preclinical results suggest that this innovative approach may effectively address the resistance challenges often faced in solid tumor CAR-T trials.

In addition to progressing with its AML trial, CERO has reported promising preclinical findings that demonstrate CER-1236’s efficacy in treating ovarian cancer cells without causing toxicity in animal models, marking an important advancement in their research efforts. CEO Chris Ehrlich acknowledged the commitment of the team, stating, “Their incredible efforts cannot be understated,” as they prepare to provide updates on their clinical trials in the near future. This commitment highlights CERO’s dedication to transforming cancer treatment through its proprietary Chimeric Engulfment Receptor T cell (CER-T) technology.

Related news for (CERO)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.